The Venture Codex

Participated · Series C · Nov 2023

Neurophet develops AI-driven medical software for neurology, including brain MRI and PET analysis, stimulation simulation, and region-of-interest research tools. Its product suite includes Neurophet AQUA (brain MRI imaging analysis), Neurophet SCALE PET (brain PET scan analysis), Neurophet tES/TMS Lab (stimulation simulation), and Neurophet SegPlus (ROI research tool). The company focuses on diagnosis support, treatment guides, and treatment-device software for brain diseases using advanced AI. In November 2023 Neurophet secured KRW 20.0 billion in a Series C financing. The firm plans to use the funds to release a comprehensive Alzheimer’s dementia solution next year. The funding is intended to support continued product development and commercial rollout of its AI-driven brain imaging offerings.

Participated · Series A · Jun 2021

Ringle provides one-on-one video English lessons with native-speaking tutors from prestigious universities and AI-based analytics that produce feedback on speech pace, vocabulary, and expression range. The company claims over 700 manually vetted tutors and 100,000 users, with lessons bookings up 390% year-over-year and revenue that has grown three times every year since founding. Ringle uses thought-provoking, domain-rich learning materials aimed at business and academic English and emphasizes highly trained tutors. Planned uses of proceeds include developing original educational content, adding a subscription option for premium content, expanding globally and into new age groups, and launching a junior program for students aged 10 and above. Ringle is also investing in its tech platform in collaboration with KAIST HCI to build a language diagnostics system measuring Complexity, Accuracy, and Fluency and adding more review features to track learning goals. The company operates from Seoul and a team in San Mateo, CA, and was founded in 2015 by two Stanford MBA graduates.

Participated · Series B · Nov 2020

Rebus Biosystems develops an automated spatial omics instrument that pairs its patented Synthetic Aperture Optics (SAO) with custom microfluidics and image processing to deliver subcellular resolution across large tissue sections. The SAO system provides the resolution and sensitivity of a 100X oil lens while retaining the breadth and depth of a 20X air lens, and captures data up to 100 times faster than other imaging‑based spatial omics methods that rely on 100X lenses and z‑stacking. The platform is integrated with optimized assay kits for spatial transcriptomics, and early access is available through the Spatial Omics as a Service program, with academic groups and pharmaceutical companies already using the data. The company plans to launch a fully integrated, automated, standalone instrument and assay kits in early 2021, with expanded multi‑omic applications to follow. Rebus has already deployed hardware to laboratories worldwide and positions its product to increase throughput without compromising biological fidelity. The company rebranded from Optical Biosystems to Rebus Biosystems.